Cytodyn Inc (CYDY)

[daemon57]

CytoDyn to Hold Conference Call on September 2 to Provide Update on Timelines for Multiple Regulatory and Clinical Initiatives Including COVID-19 Potential Approvals
Download as PDFAugust 28, 2020 4:37pm EDT
VANCOUVER, Washington, Aug. 28, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer, Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, M.D., Senior Science Advisor, will host an investment community conference call on Wednesday, September 2, 2020, to provide a comprehensive update on the most anticipated timelines for multiple regulatory and clinical initiatives, including COVID-19 potential approval timelines in U.S. and U.K. The conference call will focus on the following key agenda items:

Details of the current discussions with MHRA in regards to fast track approval for COVID-19
Status of Emergency Use Approval for COVID-19, CD10 trial in U.S.
Detail discussions of the cancer results and discussions from invited guest (from Creative MicroTech) on the leronlimab potential in all cancers based on current results in the last 1 year
HIV – BLA submission in U.S. and U.K.
HIV – cure project
NASH timeline
Potential other trials
Scientific Advisory Board
NASDAQ uplist
Management will dedicate approximately 45 minutes to address questions from analysts and investors.

Date: Wednesday, September 2, 2020
Time: 1:00 pm PT / 4:00 pm ET
Dial-In: 877-407-8291 U.S. / 201-689-8345 International